Strategic investment brings together Bullseye's biosensing technology with ABKO's engineering and manufacturing capabilities to accelerate product development and global commercialization.

HOBOKEN, New Jersey — Bullseye Biodevices, Inc., a medical technology startup developing intelligent biosensing solutions for healthcare, today announced a $1.3 million strategic investment from ABKO Co., Ltd., a South Korea-based technology company.

The investment marks an important milestone in Bullseye's transition from technology development toward product optimization, manufacturing readiness, and commercialization. Through the strategic relationship, Bullseye and ABKO plan to combine Bullseye's expertise in biomedical sensing and minimally invasive technologies with ABKO's capabilities in product engineering, manufacturing, and commercialization.

Bullseye is developing a novel biosensing platform designed to provide physicians with quantitative information about tissue properties during minimally invasive procedures. The technology is intended to support more informed intraoperative decision-making while remaining compatible with the increasingly robotic and minimally invasive nature of modern surgery.

Since its founding in 2024, Bullseye has advanced its technology through prototype development, tissue testing, intellectual property development, and customer discovery with clinicians and industry stakeholders. The company has also received support through the National Science Foundation's Small Business Technology Transfer (NSF STTR Phase I) program as it continues to translate its technology toward clinical application.

“This investment represents much more than financial support for Bullseye,” said Donnie Mir, Co-Founder and CEO of Bullseye Biodevices. “ABKO brings engineering, manufacturing, and commercialization capabilities that strongly complement our team’s expertise in biosensing and biomedical device development. Together, we have an opportunity to accelerate our path toward commercialization and expand the reach of our technology in the U.S., South Korea, and global markets.”

“This investment represents an important step in advancing our biosensing technology toward clinical translation,” said Jinho Kim, Ph.D., Co-Founder and Chief Technology Officer of Bullseye Biodevices. “It provides us with additional resources and capabilities to accelerate development, strengthen validation, and ultimately bring our technology closer to physicians and patients.”

The investment will support Bullseye's next phase of development, including further refinement of its sensing hardware, product and manufacturing optimization, development of AI-enabled diagnostic capabilities, preclinical validation, and preparation for future regulatory activities.

The companies also intend to explore opportunities for collaboration in the United States, South Korea, and other global markets, with the long-term objective of expanding the application of intelligent biosensing technologies in minimally invasive and robotic surgery.

About Bullseye Biodevices, Inc.

Bullseye Biodevices, Inc. is a U.S.-based medical technology company developing intelligent biosensing solutions for disease detection and minimally invasive surgery. The company's technology combines mechanical tissue characterization, miniaturized sensing, and data-driven analysis to provide physicians with quantitative information that may support real-time clinical decision-making.

About ABKO Co., Ltd.

ABKO Co., Ltd. is a publicly listed South Korean technology company specializing in consumer electronics, computer peripherals, gaming equipment, and related hardware products. With expertise in product engineering, manufacturing, and commercialization, ABKO has extensive experience bringing technology products from design to market. Through its strategic investment in Bullseye Biodevices, ABKO is extending these capabilities into the biomedical technology sector to support the development and commercialization of next-generation medical technologies.